Tradestie Institutional Equity Comparison Engine

HALO vs SYRE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HALO Overall Edge

HALO Captures Institutional Edge (2โ€“2 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Halozyme Therapeutics, Inc. (HALO) driven by superior Valuation, Growth & Margin while SYRE counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, HALO trades at 9.5x Forward P/E with 56.7% operating margin (+39.2% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, HALO sits in CONSOLIDATION (26th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner HALO
HALO 9.5x vs SYRE N/M Fwd P/E
Growth & Margin Winner HALO
Op Margin 56.7% vs 0.0% ยท YoY +39.2% vs +0.0%
Momentum & Technical Winner SYRE
1Y +36.9% vs +341.7% ยท 52W Pos 50% vs 88%
Options & Structure Winner SYRE
CONSOLIDATION (26th %ile IV) vs UNCLASSIFIED (10th %ile IV)
HALO NASDAQ
Halozyme Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$97.43
-2.83% 1D
Market Cap $11.5B
1M Return -20.03%
1Y Return +36.86%
Forward P/E 9.5x
Unified AI Score
59.9 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 70.0 Mom 55.0
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: HALO +36.86% SYRE +341.74% Spread: +304.88 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
HALO TTM Op. Margin: 56.7% SYRE TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HALO vs SYRE. Trailing 12-month operating profitability (HALO 56.7% vs SYRE 0.0%) and valuation multiples (HALO 9.5x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: HALO (8) vs SYRE (2)
Institutional Metric HALO SYRE Criterion Row Winner
Market Capitalization Scale $11.5B $9.8B Larger Scale HALO
Trailing P/E Ratio Valuation 25.2x N/M Lower Multiple HALO
Forward P/E Ratio Valuation 9.5x N/M Lower Multiple HALO
Revenue Growth (YoY) Growth +39.2% +0.0% Higher Growth HALO
Operating Margin (TTM) Profitability 56.7% 0.0% Higher Margin HALO
Net Profit Margin Profitability 26.9% 0.0% Higher Margin HALO
Return on Equity (ROE) Capital Efficiency 216.4% -35.0% Higher ROE HALO
52-Week Range Position Momentum 50% ($61โ€“$134) 88% ($22โ€“$111) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 0.57ฮฒ ยท 59% Vol 1.75ฮฒ ยท 59% Vol Lower Realized Risk SYRE
Unified Institutional Score Composite Signal 59.9 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite HALO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full HALO vs SYRE Buy Guide
HALO CONSOLIDATION
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live HALO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither HALO nor SYRE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.